Clinical trials
HIV-1-infection clinical trials
Below are recruiting hiv-1-infection clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07645287RecruitingPhase 2
New HIV Combination Therapy for People on Biktarvy
This study tests a new HIV medication (GS-3242) combined with lenacapavir against your current Biktarvy regimen. Both are all-oral treatments for people whose HIV is well-controlled.
Phoenix, ArizonaAges 18 years+ - NCT05215704Recruiting
Lab study of dormant HIV using samples from you
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
RotterdamAges 18 years+ - NCT06492187Recruiting
Survey to see if you qualify for infectious disease studies
This trial is a quick survey to see if you might be eligible for future infectious disease studies. It helps researchers understand your health background and find the right study for you.
Brooklyn, New YorkAges 18 years+ - NCT07725042Recruiting
HIV infection study in Hong Kong for newly diagnosed adults
This study looks at people newly diagnosed with HIV in Hong Kong. It aims to understand patterns of infection to improve care.
North PointAges 18 years+ - NCT06631365RecruitingPhase 2
PrEP on demand: a pilot study for men who have sex with men
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
San Francisco, CaliforniaAges 18 years+ - NCT07719491RecruitingPhase 1
Study of GS-0415 in People with HIV
This study tests a new drug, GS-0415, for people with HIV. The study will see if this drug can help control the virus. Participants will continue taking their regular HIV medication.
Los Angeles, CaliforniaAges 18–65 - NCT07708727RecruitingPhase 2/Phase 3
Injectable HIV treatment vs daily pill for new patients
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
Torrance, CaliforniaAges 18 years+ - NCT07698600RecruitingPhase 1
Safety test of a new HIV vaccine in adults with or without HIV
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
Houston, TexasAges 18–50 - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+ - NCT00537966Recruiting
Study of new HIV infections in the Zurich area
This study enrolls people whose HIV infection is very recent or newly diagnosed (within the last few months). The researchers want to better understand early stages of HIV to improve how doctors identify and track new infections.
ZurichAges 18 years+ - NCT04513626RecruitingPhase 2
HIV trial testing doravirine plus raltegravir in adults
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
Paris, Île-de-France RegionAges 18 years+ - NCT07476339RecruitingPhase 4
Returning to HIV Care with Biktarvy
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
Clearwater, FloridaAges 18 years+ - NCT07392372RecruitingPhase 1
Testing the safety of BNT351 in people with and without HIV
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Chicago, IllinoisAges 18–65 - NCT07370649Recruiting
Long-acting HIV injectable study for subtype A6
This study looks back at medical records of people with HIV-1 who have received a long-acting injectable treatment called cabotegravir plus rilpivirine. It aims to see how well this treatment works for people with a specific HIV subtype (A6).
PragueAges 18 years+ - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT07275606RecruitingPhase 1/Phase 2
Testing HIV prevention medicine cabotegravir in newborns
This study tests a long-acting injectable HIV prevention medicine called cabotegravir in newborn babies who were exposed to HIV. The goal is to see if it can help protect them from getting HIV.
Parow ValleyAges Up to 1 week - NCT07266831RecruitingPhase 2/Phase 3
New HIV treatment for people not yet on medication
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
Los Angeles, CaliforniaAges 18 years+ - NCT06902142Recruiting
HIV treatment study with Bictegravir medication monitoring
This study looks at how well HIV-1 patients take their medication (bictegravir/emtricitabine/tenofovir) and how that relates to how well the virus is controlled. It uses a special pill bottle cap that records when the bottle is opened, so the research team can see if the medicine is being taken as prescribed.
CaenAges 18 years+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT07186244Recruiting
HIV Prevention Study for People Starting or Taking PrEP
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
Chieti, AbruzzoAges 18 years+ - NCT04098315Recruiting
HIV drug-resistance patient registry study for people 14+
This study is a registry (a way to collect and organize information) for people living with HIV who have drug-resistant virus. It may help researchers better understand how resistant HIV behaves and how to manage treatment over time.
Milan, MIAges 14 years+ - NCT00796263RecruitingPhase 3
Test HIV medicines for people with new or long-term HIV
This Phase 3 study looks at antiretroviral treatment (HIV medicines) for adults with either recent (acute) or long-term (chronic) HIV. It’s designed to see how well and safely ongoing HIV treatment works, and it may help you get structured care and monitoring.
BangkokAges 18 years+ - NCT06928090Enrolling by invitation
HIV trial testing two-med combo for first-time treatment
This trial studies a two-drug pill (DTG/3TC) for people who have never taken HIV medication before. It aims to see if this simpler treatment is effective and safe for controlling HIV-1.
DaejeonAges 19 years+ - NCT06640192RecruitingPhase 2
High-dose HIV drugs to clear hidden virus
This study tests whether giving very high doses of your current HIV meds can flush out hidden HIV that stays in the body even when the virus is undetectable. It might help find a way to reduce or eliminate the reservoir of latent HIV.
Madrid, MadridAges 18–60
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
HIV-1-infection trials by city
Studies with a site in or near these metro areas.
HIV-1-infection trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hiv-1-infection?
- Yes. Clin2 currently lists 86 recruiting hiv-1-infection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv-1-infection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv-1-infection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.